Pilot study of bevacizumab and irinotecan in children with recurrent or refractory solid tumors.
Phase 1
- Conditions
- Recurrent or refractory solid tumors
- Registration Number
- JPRN-UMIN000005108
- Lead Sponsor
- Osaka City General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
Has a double cancer. Has a cardiac disease for which treatment is necessary. Has a psychosis or mental disorder.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determine the DLTs.
- Secondary Outcome Measures
Name Time Method Estimate the rate of treatment-related toxicity.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bevacizumab and irinotecan combination in pediatric recurrent/refractory solid tumors?
How does bevacizumab plus irinotecan efficacy compare to standard chemotherapy in pediatric recurrent/refractory solid tumors?
Which biomarkers predict response to anti-VEGF and topoisomerase I inhibitor therapies in pediatric refractory solid tumors?
What adverse events and management strategies are associated with bevacizumab and irinotecan in pediatric oncology?
What alternative anti-angiogenic agents or combination therapies exist for pediatric recurrent/refractory solid tumors besides bevacizumab and irinotecan?